Actively Recruiting
Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management
Led by Ain Shams University · Updated on 2026-03-11
25
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to compare the efficacy of anti-Xa based versus weight-based enoxaparin dosing and to evaluate anti-Xa levels as a predictive tool for clinical outcomes in burn patients
CONDITIONS
Official Title
Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (21 years or older) admitted to the burn unit with thermal burns covering 20% to less than 60% total body surface area
- Admission to burn intensive care unit within 48 hours of burn injury
- Indication for venous thromboembolic event prophylaxis such as immobilization or surgical intervention
- Ability to provide informed consent
You will not qualify if you...
- Pre-existing blood clotting disorder or anticoagulant therapy before injury
- Severe other health problems such as end-stage kidney failure, advanced cancer, or liver disease
- Need for therapeutic anticoagulant therapy
- Weight less than 45 kg or greater than or equal to 150 kg
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ain Shams University
Cairo, Abbassia, Egypt, 00202
Actively Recruiting
Research Team
D
Doaa Ahmed Diaa El din Ibrahim, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here